Mondego Bio Starts First-in-Human Trial of Oral PTPN2/PTPN1 Inhibitor
Image
Cantanhede – November 05, 2026 -- Mondego Bio has started a first-in-human Phase 1 study of MB-388, an oral dual PTPN2/PTPN1 inhibitor built to overcome resistance to cancer immunotherapy, with initial human pharmacokinetic and pharmacodynamic data due in December 2026.
Phase 1a tests dose escalation in healthy volunteers
The randomized, double-blind, placebo-controlled study will evaluate single and multiple ascending doses of MB-388. It will assess safety and tolerability, characterize pharmacokinetics and measure target engagement using blood-based pharmacodynamic biomarkers.
CEO Nikolay Savchuk said the study will define the relationship between exposure, pathway engagement and tolerability ahead of the planned patient study.